Skip to main content
main-content

Zeitschrift

Advances in Therapy

Advances in Therapy OnlineFirst articles

23.09.2021 | Commentary Open Access

Variability in Contraceptive Clinical Trial Design and the Challenges in Making Comparisons Across Trials

Clinical trials of contraceptives have often differed in their study designs, making cross-trial comparisons difficult. This brief report outlines some of the technical design features that can vary from trial to trial. For example, the overall …

20.09.2021 | Original Research Open Access

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial

Migraine preventive medications are more likely to be prescribed for patients with more severe headache-related disability [ 1 ]. However, persistence on traditional standard-of-care migraine preventive medications is quite poor, and the primary …

19.09.2021 | Original Research Open Access

Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)

Anemia of dialysis-dependent (DD) CKD is associated with reduced quality of life and increased risk of hospitalization and mortality [ 1 , 2 ]. Anemia of DD CKD is commonly treated with erythropoiesis-stimulating agents (ESAs), alongside oral or …

18.09.2021 | Original Research Open Access

Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison

Bothersome symptoms of overactive bladder (OAB) affect an estimated 30 million adults in the USA [ 1 ]. Clinical guidelines recommend behavioral therapy with or without pharmacologic management as first-line treatment for OAB and oral …

15.09.2021 | Original Research Open Access

Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR

Parkinson’s disease (PD) is the second most common neurodegenerative disease, involving both motor and non-motor symptoms (NMS). Depression is a very frequent NMS that seriously affects quality of life (QoL) in PD, even in subclinical patients [ 1 …

Aktuelle Ausgaben

Über diese Zeitschrift

Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.

Advances in Therapy is of interest to a broad audience of researchers, industry and healthcare professionals, receiving submissions from all over the world, and publishes original research and authoritative reviews focusing on new and existing therapies and interventions, areas of unmet need and general topics of interest to the medical community.

Moving forward from traditional publishing, Advances in Therapy offers a range of additional features designed to increase visibility and readership. Each paper is accompanied by a bulleted slide summary, giving a time-efficient overview of the content to a wider readership. Articles also have the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are open access and are peer reviewed to the same high standard as the article itself.

Upon acceptance of your article for publication, you will be required to pay an article processing charge of £420/$660 per typeset page. Additionally, Advances in Therapy offers an open access option for all articles submitted to the journal. If you choose open access publication you will be required to pay an additional fee of £2000/$3000 upon acceptance of your article.

Please note: Advances in Therapy's open access articles are published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0.

For more information about the journal, please contact victoria.john@springer.com or see the News page for the latest journal offers.

Weitere Informationen

Neu im Fachgebiet Innere Medizin

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin 

Bildnachweise